New drug combo tested in fight against advanced lung cancer
Disease control
Terminated
This study tested a new oral drug, SLC-391, combined with the immunotherapy drug pembrolizumab in people with advanced non-small cell lung cancer (NSCLC). The first part aimed to find a safe dose for the combination. The second part aimed to see if the combination could help stop…
Phase: PHASE1, PHASE2 • Sponsor: SignalChem Lifesciences Corporation • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC